Tsukui, Tatsuya http://orcid.org/0000-0003-3100-6934
Sun, Kai-Hui
Wetter, Joseph B.
Wilson-Kanamori, John R.
Hazelwood, Lisa A.
Henderson, Neil C. http://orcid.org/0000-0002-2273-4094
Adams, Taylor S.
Schupp, Jonas C. http://orcid.org/0000-0002-7714-8076
Poli, Sergio D.
Rosas, Ivan O.
Kaminski, Naftali http://orcid.org/0000-0001-5917-4601
Matthay, Michael A.
Wolters, Paul J.
Sheppard, Dean http://orcid.org/0000-0002-6277-2036
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL123423, HL108794)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
AbbVie
Article History
Received: 28 June 2019
Accepted: 20 March 2020
First Online: 21 April 2020
Competing interests
: D.S. is a founder of Pliant Therapeutics and has received research funding from Abbvie, Pfizer and Pliant Therapeutics. He serves on the Scientific Review Board for Genentech, xCella Biosciences and Optikira. M.A.M. has received research funding from Bayer Therapeutics and is a consultant for Cerus Therapeutics and Gen1e Life Sciences. T.S.A., J.C.S., S.P., I.O.R., and N.K. are inventors on a provisional patent application (62/849,644), Yale University and Brigham and Women’s Hospital, Inc. that covers methods related to IPF associated cell subsets. N.K. served as a consultant to Biogen Idec, Boehringer Ingelheim, Third Rock, Pliant, Samumed, NuMedii, Indaloo, Theravance, LifeMax, Three Lake Partners, Optikira over the last 3 years and received non-financial support from MiRagen.